Aa
Alnylam new HBV drug, 2.3 log knockdown HBsAg
-IMO, with all the new drug candidates being introduced, the next few years will bring a "Sovaldi" for HBV to the market. This is similar technology to ARC-520 , so it provided some validation to what they are doing
Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees
http://finance.yahoo.com/news/alnylam-announces-rnai-therapeutic-program-120000812.html
Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees
http://finance.yahoo.com/news/alnylam-announces-rnai-therapeutic-program-120000812.html
No problem, I really think that HBV will be readily cured in the next 4 years with a non PEG combo therapy. It is encouraging that so many companies seem to be joining the fray and having initial stage success. I am vey excited to see the phase 2a ARC results in Q3
This news was just released today, and it is even better that ARC-520's chimp results IMO. We are however dealing with one chimp in ARC and 4 in Analyam.
The key takeaway is that both are RNAi companies and both have shown significant knockdown after just one dose. Additionally they have both demonstrated a likely therapeutic flare. ARC at this point may be 1-2 years ahead of ANLY in terms of development as they are currently in stage 2a trials.
If either can contistantly maintain a 2 log knockdown, that would put virtually all those with chronic HBV in the sweet spot (HBsAg >1000). This would hopefully allow either natural immune system response or INT to clear the SA and induce HBsAB
The key takeaway is that both are RNAi companies and both have shown significant knockdown after just one dose. Additionally they have both demonstrated a likely therapeutic flare. ARC at this point may be 1-2 years ahead of ANLY in terms of development as they are currently in stage 2a trials.
If either can contistantly maintain a 2 log knockdown, that would put virtually all those with chronic HBV in the sweet spot (HBsAg >1000). This would hopefully allow either natural immune system response or INT to clear the SA and induce HBsAB
Therapeutic Flare induced?
Of interest, two of four animals showed mildly elevated liver transaminase levels of about two-to-three fold approximately one-to-two months post dosing that included increases in interferon-gamma and interleukin-6, suggestive of potential “therapeutic flares” related to immune clearance of infected hepatocytes.
Of interest, two of four animals showed mildly elevated liver transaminase levels of about two-to-three fold approximately one-to-two months post dosing that included increases in interferon-gamma and interleukin-6, suggestive of potential “therapeutic flares” related to immune clearance of infected hepatocytes.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
http://www.fool.com/investing/general/2014/03/14/its-official-merck-now-owns-part-of-alnylam.aspx